Royalty Pharma announced a 13% hike in its quarterly dividend to $0.17 per share from $0.15.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Royalty Pharma (RPRX) said that the new quarterly dividend would be paid by Mar. 15 to shareholders of record as of Feb. 19. Its annual dividend of $0.68 per share now reflects a dividend yield of 1.3%.
Earlier on Dec. 7, Royalty Pharma announced that it will acquire a royalty interest in Orladeyo therapy and BCX9930 from BioCryst Pharmaceuticals. Royalty Pharma, along with Athyrium Capital Management, will provide about $325 million in funding for BioCryst to support the launch of Orladeyo therapy to treat hereditary angioedema disorder and the development of BCX9930, which is an oral Factor D inhibitor. (See RPRX stock analysis on TipRanks)
Meanwhile, on Nov. 9, UBS analyst Navin Jacob upgraded Royalty Pharma stock from Hold to Buy. Jacob said, “Creative transactions, such as the BHVN [Biohaven Pharmaceutical Holding Company Ltd.] financing and NPV [net present value] positive Cystic Fibrosis deal, increases the likelihood of low double digit IRR [internal rate of return] on new investments.”
The analyst added, “RPRX’s low cost of debt (~2%) & 0% tax rate creates an opportunity to invest in royalty streams and in biotech companies at more favorable terms than competitors.”
However, Jacob lowered the price target to $51 (0.53% downside potential) from $52. Shares have gained 16.1% since it was listed on the NASDAQ on June 16, 2020.
Related News:
Bank OZK Hikes Dividend; Street Is Cautiously Optimistic
Glacier Bancorp To Pay Special Dividend; Street Sees Downside Risk
Ensign Ramps Up Dividend By 5%; Street Is Bullish